Feature | May 14, 2013

Study Compares Multidisciplinary Convergent Procedure to Endocardial Catheter Ablation to Treat AF

The CONVERGE IDE clinical trial may set a new standard of care in AF ablation

The EPi-Sense-AF Guided Coagulation System.

May 14, 2013 — nContact Inc. said it received conditional approval for an investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA) to begin enrollment in the CONVERGE trial, a multicenter, prospective, randomized study evaluating patients with symptomatic persistent atrial fibrillation (AF). AF is the most common cardiac arrhythmia, a condition that disrupts the ability of the atria (upper chambers of the heart) to beat regularly and pump blood efficiently. The CONVERGE study, designed to investigate the  epicardial/endocardial Convergent Procedure, combines the cardiac ablation expertise, techniques, and technologies of both electrophysiologists and cardiothoracic surgeons.

"The Convergent Procedure may set a new standard of care in AF ablation," said Kenneth C. Civello Jr., M.D., MPH, of Our Lady of the Lake Hospital, Baton Rouge, La. "This pioneering clinical study will evaluate the unmet need of the large persistent AF patient population for whom conventional endocardial ablation has been limited."

The multidisciplinary Convergent Procedure is performed as a single procedure in the electrophysiology lab. The epicardial component of the procedure is completed with no chest incisions, using the proprietary transdiaphragmatic approach that requires a 2 cm incision in the abdomen, providing the surgeon direct visualization to create lesions across the atrium.

"The convergent procedure is the least invasive option among multidisciplinary ablation techniques; there is no chest violation, no heart dissection, and no lung deflation," said Peter Walts, M.D., of St. Vincent Medical Group, Indianapolis, Ind. "By providing direct visualization and closed-chest access to the posterior left atrium, the convergent procedure may address major limitations experienced in traditional endocardial ablation."

The CONVERGE trial will randomize patients 2:1 between nContact's epicardial/endocardial convergent procedure using the EPi-Sense-AF
Guided Coagulation System with VisiTrax and standalone endocardial ablation using fluid-irrigated catheters for the treatment of persistent AF. The primary effectiveness endpoint is freedom from AF, atrial tachycardia, and atrial flutter without the use of new antiarrhythmic drugs. Secondary effectiveness endpoints include the reduction of AF burden and changes in Quality of Life measures from baseline: patients will be followed for 12 months post-procedure. Primary and secondary safety endpoints are the incidence of major adverse events following the initial procedure and through the 12-month follow-up period.

For more information: www.ncontactinc.com

 

Related Content

Medtronic, sudden cardiac death, SCD, DISCOVERY, Oregon SUDS, study, ICDs, gene
News | Sudden Cardiac Arrest| August 31, 2015
Medtronic plc announced first-of-its-kind findings from two independent studies that have identified a gene associated...
News | Heart Failure| August 28, 2015
August 28, 2015 — BioControl Medical said it has completed enrollment in its INOVATE-HF (INcrease Of VAgal TonE in He
BioSig Technologies, research agreement, UCLA, Pure EP System, EP lab, ventricular tachycardia model, VT
Technology | EP Lab| August 20, 2015
BioSig Technologies announced it has signed a sponsored research agreement with the regents of the University of...
Biotronik, BioCONTINUE study, CRT-D, defibrillator, cardiac resynchronization therapy device, heart failure, first replacement
News | Cardiac Resynchronization Therapy Devices (CRT)| August 17, 2015
Biotronik announced that the first patient has been enrolled in the BioCONTINUE clinical trial (BIOtronik study to...
CMS, additional participants, Bundled Payments for Care Improvement initiative, Medicare, eipsodes of care
News | Business| August 17, 2015
The Centers for Medicare & Medicaid Service (CMS) announced that over 2,100 healthcare facilities have agreed to...
Biotronik, BIOGUARD-MI Study, BioMonitor, cardiac arrhythmias, early detection, remote monitoring
News | Implantable Cardiac Monitor (ICM)| August 11, 2015
Biotronik announced the first enrollments in the BIO|GUARD-MI1 study. The study will investigate whether the early...
Boston Scientific, Preventice Solutions, equity investment, sales cooperation agreement, cardiac monitoring

BodyGuardian product family. Image courtesy of Preventice Solutions.

News | Remote Monitoring| August 11, 2015
Boston Scientific has become a significant shareholder and will become the exclusive worldwide sales and marketing...
Passive Elastography, TTP, U.K., ablation, atrial fibrillation
News | Cardiovascular Ultrasound| August 10, 2015
The Technology Partnership (TTP), a U.K.-based research and product development company, has made major advances in the...
Boehringer Ingelheim, RE-DUAL PCI, RE-CIRCUIT, Pradaxa, first U.S. patients,
News | Antiplatelet and Anticoagulation Therapies| August 05, 2015
August 5, 2015 — Boehringer Ingelheim announced the first U.S.
Overlay Init